BioCentury | Dec 3, 2020
Finance

Merck’s divestiture of Moderna stake brought ‘substantial’ return, but shares’ run continued afterward

Merck sold its shares in Moderna at a price at least three times their value at the beginning of 2020, although the biotech’s value has continued to rise since the divestiture’s completion as its COVID-19...
BioCentury | Dec 2, 2020
Product Development

U.S., U.K. recommend healthcare workers, long-term care residents among highest priority for COVID-19 vaccination

CDC Director Robert Redfield has adopted the recommendation by the agency’s Advisory Committee on Immunization Practices to prioritize an estimated 21 million healthcare workers and 3 million residents of long-term care facilities in the initial...
BioCentury | Dec 2, 2020
Product Development

Azar touts mAb COVID-19 therapies but NIH isn’t convinced

The Trump administration sent mixed messages about mAbs for COVID-19 Wednesday as HHS Secretary Alex Azar urged the media to encourage Americans to seek the therapies and an NIH panel said there aren’t...
BioCentury | Dec 2, 2020
Product Development

EUA of J&J COVID-19 vaccine possible in February, Warp Speed’s Slaoui says

The Janssen unit of Johnson & Johnson could complete the U.S. government-supported Phase III trial of its COVID-19 vaccine candidate by January, and if it is successful receive emergency use authorization from FDA in February,...
BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

The addition of $43 million in new series E cash to Canbridge’s balance sheet may better prepare it for a listing, but the company isn’t saying when or where it might go public. At the...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Inhibiting BMI1 and BCL-2 to treat diffuse intrinsic pontine glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Inhibiting epigenetic regulator BMI1 alone or in combination with BCL-2 inhibition could treat diffuse intrinsic pontine glioma (DIPG), an aggressive childhood brain cancer. A screen in two human DIPG...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

DISEASE CATEGORY: Ophthalmic disease INDICATION: Ocular hypertension Penn researchers showed that NLY01 from Neuraly Inc., could treat ocular hypertension. In mice modelling ocular hypertension, the pegylated exenatide reduced retinal ganglion cell death and mRNA levels of...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer; melanoma PCSK9 inhibition could treat melanoma, breast, colorectal and other cancers, and enhance the efficacy of PD-1 inhibitors. In cohorts of melanoma, liver, pancreatic, bladder, lung, kidney and...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Apoptosis regulator MCL1 as an Alzheimer’s target

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease (AD) Blocking MCL1, which inhibits apoptosis, could treat Alzheimer’s disease. A high-throughput screen in HEK cells of 2,204 drug candidates or FDA-approved drugs yielded 20 agents, including an MCL1...
BioCentury | Dec 2, 2020
Regulation

With first authorization worldwide for BioNTech-Pfizer COVID-19 vaccine, U.K. asserts speedy review was thorough

The U.K. will start its COVID-19 vaccination program next week following MHRA’s authorization of BNT162b2 from partners BioNTech and Pfizer. The news comes as some European lawmakers criticized the speed of MHRA’s approval. It’s the first authorization...
Items per page:
1 - 10 of 68924